Showing results (1-10 of 24) with videos related to
Sort By:
Pageof 3
Antiviral Therapy|November 18, 2009
Does RNA interference provide new hope for control of chronic hepatitis B infection?Rachel Wilson, Damian Purcell, Hans J Netter, et al.Antiviral Research|November 4, 2015
The non-pathogenic Henipavirus Cedar paramyxovirus phosphoprotein has a compromised ability to target STAT1 and STAT2Kim G Lieu, Glenn A Marsh, Lin-Fa Wang, et al.Frontiers in Microbiology|July 8, 2021
Hepatitis Delta Virus (HDV) and Delta-Like Agents: Insights Into Their OriginHans J Netter, Marilou H Barrios, Margaret Littlejohn, et al.Applied Microbiology and Biotechnology|October 23, 2013
Production, characterization, and immunogenicity of a secreted form of Plasmodium falciparum merozoite surface protein 4 produced in Bacillus subtilisG Chittibabu, Charles Ma, Hans J Netter, et al.Vaccine|June 12, 2003
Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccineHans J Netter, Wai-Ping Woo, Robert Tindle, et al.Antiviral Research|December 6, 2011
Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunitsWan-Shoo Cheong, Michiko Hyakumura, Lilly Yuen, et al.Vaccine|March 12, 2013
Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cellsJessica M Moffat, Wan-Shoo Cheong, José A Villadangos, et al.Pathogens (Basel, Switzerland)|April 22, 2017
Subverting Host Cell P21-Activated Kinase: A Case of Convergent Evolution across PathogensSimona John Von Freyend, Terry Kwok-Schuelein, Hans J Netter, et al.Nature Reviews. Gastroenterology & Hepatology|May 30, 2020
The evolution and clinical impact of hepatitis B virus genome diversityPeter A Revill, Thomas Tu, Hans J Netter, et al.Nature Communications|May 9, 2017
Signalome-wide assessment of host cell response to hepatitis C virusGholamreza Haqshenas, Jianmin Wu, Kaylene J Simpson, et al.Pageof 3